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Aims Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) play a role in left ventricular structural remo-
delling. The aim of our study was to analyse MMP-2 and TIMP-1 levels as predictors of poor response to cardiac
resynchronization therapy (CRT).
Methods
and results
A cohort of 42 CRT patients from our centre was prospectively evaluated at baseline and after 12-month follow-up.
MMP-2 and TIMP-1 assays were performed prior to CRT implant. Cardiac resynchronization therapy responders
were deﬁned as patients who survived, were not transplanted, and increased their basal 6 min walking distance
test (6MWDT) by ≥10% or improved their NYHA functional class. Overall, 25 patients (60%) were classed as
responders. At 12-month follow-up, six patients (14.2%) had died and one (2.4%) patient had been transplanted.
Compared with responders, non-responders had higher levels of TIMP-1 (277+59 vs. 216+46 ng/mL,
P ¼ 0.001), MMP-2 (325+115 vs. 258+56 ng/mL, P ¼ 0.02), and creatinine (1.76+0.8 vs. 1.25+0.3 mg/dL,
P ¼ 0.01). In a multivariate analysis, TIMP-1 was the only independent predictor of non-response to CRT [OR
0.97, 95% (CI 0.96–0.99) P ¼ 0.005]. TIMP-1≥248 ng/mL predicted non-response with 71% sensitivity and 72%
speciﬁcity.
Conclusion TIMP-1 is an independent predictor of non-response in patients treated with CRT.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Cardiac resynchronization therapy (CRT) is considered a class I
indication in patients with stable heart failure, NYHA functional
class III-IV, ejection fraction (EF) ≤35%, and wide QRS
.120 ms.
1 However, the percentage of patients who do not
respond to CRT is about 30%.
Left ventricular (LV) remodelling plays an important role in the
progression of heart failure.
2,3 Degradation of the myocardial
extracellular matrix contributes to LV remodelling
4,5 and the
proteolytic enzyme system responsible for the degradation is
matrix metalloproteinases (MMPs).
6,7 This enzyme system is con-
trolled by a group of endogenous proteins called tissue inhibitors
of MMPs (TIMPs). Some studies have reported an increase in
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advanced heart failure.
8 Moreover, increased levels of TIMP-1
and MMP-2 are associated with poor prognosis in these
patients.
9,10
The ﬁrst objective of our study was to determine whether basal
MMP-2 and TIMP-1 levels could predict response to CRT. A
second objective was to compare the levels of MMP-2 and
TIMP-1 in coronary sinus (CS) vs. peripheral blood samples in
patients with chronic heart failure.
Methods
This was a prospective single centre study approved by the Human
Research Committee at the Hospital Clinic in Barcelona.
A 1 year cohort of patients who received a CRT device in our
centre was included in the study. Inclusion criteria: (i) stable chronic
heart failure (NYHA class ≥III) despite optimal drug therapy; (ii) LV
EF ≤35%; (iii) QRS width .120 ms. In addition, patients with an EF
≤35% and an indication for cardiac pacing were also included in the
study, independent of their basal NYHA functional class.
Exclusion criteria
Patients with recent acute coronary syndrome, neoplasia, thyroid dis-
order, or chronic liver, neuromuscular, or collagen disease, as well as
those with infection or surgery in the 6 months prior to the implant,
were excluded.
Measures of clinical outcome
All patients underwent a 12-lead electrocardiogram, echocardiogram,
andclinicalevaluationpriortoimplantandat6-and12-monthfollow-up.
Heart failure symptoms, functional capacity, and quality of life were
assessed by NYHA functional class, the 6 min walking distance test
(6MWDT), and the Minnesota Living With Heart Failure test (QoL),
respectively. Pharmacological treatment was also recorded.
Two-dimensional echocardiography was performed with the patient
in left lateral decubitus position, using a commercially available system
(Vingmed Vivid-7, Milwaukee, WI, USA) equipped with a 3.5 MHz
probe. Standard M-mode and two-dimensional images were acquired
at a depth of 16 cm and stored in cine-loop format of three consecu-
tive beats. Left ventricular volumes and EF were calculated by Simp-
son’s rule from the two- and four-chamber apical views. The
presence of mitral regurgitation was assessed systematically. Colour
Doppler echocardiography was performed in all views after optimizing
gain and Nyquist limit. The severity of valvular regurgitation was deter-
mined on a qualitative scale according to the ACC/AHA guidelines for
the management of patients with valvular heart disease: mild (grade 1),
moderate (grade 2), and severe (grades 3–4).
Device implantation and programming
Right ventricular leads were positioned at the right ventricular apex.
Conventional atrial leads were used in patients in sinus rhythm or par-
oxysmal atrial ﬁbrillation. The LV electrode was inserted through the
CS into a lateral vein whenever possible. Patients in sinus rhythm
were programmed in DDD mode; patients with atrial ﬁbrillation
were programmed in VVIR mode at 75 bpm. Maximum rate was set
at 85% of the theoretical maximum heart rate. Trigger mode was acti-
vated when available.
Responder deﬁnition
Under a deﬁnition reported and validated in previous studies,
11,12
responders were deﬁned as patients who did not suffer cardiovascular
death, did not have a heart transplant, and had increased their basal
6 min walking distance test results by ≥10% at the 12-month
follow-up. In addition, for patients who did not undertake a 6 min
walking distance test, the required improvement was at least one
NYHA functional class.
13,14 The 6 min walking distance test and
NYHA functional class were assessed by an independent observer.
Biochemical analysis
AtthetimeofCRTimplant,bloodsamplesfromaperipheralveinandthe
CS were obtained simultaneously. Samples were centrifuged for 15 min
at3000 rpmand48C.Serumandplasmasampleswerestoredat 2808C
until assay. Serum MMP-2 and plasma TIMP-1 levels (Quantikine R&D
Systems, Minneapolis, Minnesota) were assessed using a commercially
available sandwich enzyme immunoassay.
Statistical analysis
Data are expressed as mean+SD and were compared using Student’s
t-test for paired and unpaired data, as appropriate. Univariate analysis
for categorical variables was performed using the chi-square test.
Kaplan–Meier estimates were calculated for mortality and differences
between groups assessed using Cox proportional hazard models. To
adjust for all prognostic factors, a multivariate Cox regression model
was ﬁtted with variables predicting non-response to CRT in the uni-
variate analysis. For all tests, a P-value ,0.05 was considered statisti-
cally signiﬁcant. The calculated sample size was 40 patients, with a
statistical power of 80% and statistical signiﬁcance of 0.05.
Results
Of 55 consecutive patients who received a CRT device in our
centre during the inclusion period, 42 (76%) were included in
the study. The main reasons for exclusion of the 13 (24%) patients
were: (i) CS not cannulated (in 3/13 patients, LV lead was
implanted by epicardial approach); (ii) consent for blood extraction
not signed (6/13), (iii) antecedents of neoplasia or chronic liver
disease (4/13).
Baseline characteristics of the 42 patients included in the study
are shown in Table 1. Nine of the included patients (21%) were
in NYHA class II at baseline with a mean LVEF of 25+7% and
were treated with CRT due to severe bradycardia and the need
for continuous ventricular pacing. Since it was impossible to
perform the 6MWDT in these patients, the response criteria
were the lack of cardiovascular events (cardiovascular death or
heart transplant) and the improvement in their stable NYHA func-
tional class (previous to the A-V block).
At 12 months after implant, 25/42 patients (60%) were classed
as responders and showed signiﬁcant improvement in functional
capacity, with an increase in 6MWDT from 262+128 to 380+
133 m (P ¼ 0.01) and in quality of life from 45+22 to 28+20
points (P ¼ 0.01). Furthermore, reverse remodelling produced a
decrease in LV end diastolic volume from 217+58 to 195+
67 mL (P ¼ 0.05) and LV end-systolic volume from 163+56 to
136+53 mL (P ¼ 0.02). Left ventricular EF increased from 27+
7t o3 3+7% (P ¼ 0.01).
Plasma tissue inhibitor of matrix metalloproteinase-1 493Serum MMP-2 and plasma TIMP-1 levels
Peripheral MMP-2 and TIMP-1 levels were higher than the CS
levels obtained (295+70 vs. 278+75 ng/mL (P ¼ 0.008) and
242+61 vs. 228+60 ng/mL, respectively). A good correlation
was observed between CS and peripheral blood samples
(Figure 1). Furthermore, TIMP-1 and MMP-2 levels were similar,
independent of the underlying aetiology of heart failure (Figure 2).
Predictors of non-response to cardiac
resynchronization therapy
Creatinine levels, CS, and peripheral TIMP-1 and MMP-2 levels
were higher in patients that did not respond to CRT (Table 2).
After adjusting for baseline covariables in the Cox regression analy-
sis, TIMP-1 was the only independent predictor of non-response to
CRT (OR 0.97, 95% CI 0.96–0.99). A peripheral TIMP-1 cut-off
value of 248 ng/mL yielded the best sensitivity and speciﬁcity
results for non-response to CRT (OR 6.8, 95% CI (1.5–31) for
TIMP-1≥248 ng/mL) (Figure 3).
TIMP-1, MMP-2, and left ventricular
reverse remodelling
TIMP-1 levels were higher in those patients without signiﬁcant LV
reverse remodelling (LVESV reduction ≥10%), whereas there
were no differences in MMP-2 levels between the patient groups
(Table 3).
Correlation between clinical response
and left ventricular reverse remodelling
Seventeen of the 25 clinical responders (68%) had signiﬁcant LV
reverse remodelling (LVESV reduction ≥10%).
Cardiovascular mortality and heart
transplant
At 12-month follow-up, 6/42 (14.2%) patients had died, 4 (9.5%)
due to end-stage heart failure and 2 (4.7%) due to sudden death;
1 patient was transplanted due to poor response to CRT.
Patients who died tended to have larger LV dimensions, lower
LV EF, worse basal NYHA functional class, and higher creatinine,
peripheral, and CS TIMP-1 levels (Table 4).
After adjusting for baseline covariables in the Cox regression
analysis, TIMP-1 level was a predictor of non-response to CRT
[OR 0.97, 95% CI (0.96–0.99) P ¼ 0.005]. Cardiovascular death
was higher in the 19 patients with TIMP-1 levels ≥248 ng/mL
than in the remaining 23 patients: 5/19 (26.3%) vs. 1/23 (4.3%)
(log-rank test 4.77, P , 0.03).
Discussion
Structural LV remodelling, a common event in the progression of
heart failure, causes progressive dilatation of the left ventricle
and pump dysfunction.
15,16 Matrix metalloproteinases have been
directly implicated in tissue remodelling because they degrade
extracellular proteins.
17
The main ﬁndings of our study are: TIMP-1 and MMP-2 levels are
positively associated with a lower probability of response to CRT;
TIMP-1 is an independent predictor of non-response to CRT;
TIMP-1 and MMP-2 levels are higher in peripheral blood samples
compared with CS samples.
MMP-2 and TIMP-1 levels positively
correlated with poor response to cardiac
resynchronization therapy
In our study, patients with higher TIMP-1 or MMP-2 levels,
whether in CS or in peripheral blood samples, had a poor clinical
response to CRT. However, after multivariate analysis, TIMP-1 was
the only independent predictor of non-response to CRT.
Our study showed higher serum MMP-2 levels in patients who
did not respond to CRT when compared with responders. There-
fore, MMP-2 was a marker of poor prognosis in terms of clinical
response to CRT. In contrast with our results, Hessel et al.
18 did
not ﬁnd any difference in baseline MMP-2 level between patients
who responded and those who did not respond to CRT. This dis-
crepancy may be explained by differences in the study design, the
use of reverse remodelling rather than clinical response as the cri-
terion for response to CRT, and the fact that no patients died or
were transplanted during follow-up in that study.
................................................................................
Table 1 Basal characteristics of patients included in the
study
N ¼ 42
Age 66+8
Male sex 35 (83.3%)
Creatinine level (mg/dL) 1.4+0.6
Atrial ﬁbrillation 8 (19%)
Ischaemic cardiomyopathy 19 (45.2%)
Ventricular arrhythmia 16 (38%)
ICD 25 (59.5%)
Beta-blockers 27 (64.3%)
ACEIs/ARBs 33 (78.5%)
Aldosterone 20 (47.6%)
NYHA functional class ≥3 33 (78.5%)
6MWDT (m) 232+126
QoL (points) 42+24
LVEDV (mL) 212+66
LVESV (mL) 162+63
LVEF (%) 27+7
Severe mitral regurgitation 5 (12%)
CS MMP-2 (ng/mL) 278+75
CS TIMP-1 (ng/mL) 228+60
Peripheral MMP-2 (ng/mL) 295+70
Peripheral TIMP-1 (ng/mL) 242+61
6MWDT, 6 min walking distance test; QoL: quality of life test (Minnesota); ICD,
internal cardioverter deﬁbrillator; LVEDV, left ventricular end-diastolic volume;
LVESV, left ventricular end systolic volume; LVEF, left ventricular ejection fraction;
MMP-2, matrix metalloproteinase-2; TIMP-1, tissue inhibitor matrix
metalloproteinase-1; CS, coronary sinus; ACEIs, angiotensin converting enzyme
inhibitors; ARBs, angiotensin receptor blockers.
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non-response in patients treated with
cardiac resynchronization therapy
Our study demonstrated an association between plasma TIMP-1
concentration and lack of response to CRT. Furthermore, after
adjusting for relevant prognostic variables in a multivariate analysis,
plasma TIMP-1 level was the only independent predictor of
non-response to CRT.
In our series, higher TIMP-1 levels were related with a poor
response to CRT more accurately than LV dimensions, LV EF,
ischaemic aetiology, and paced QRS width, all of which have
been previously identiﬁed as predictors of response.
11,14
As was described by Frantz et al.,
19 our study also showed that
TIMP-1 levels were higher in those patients who died when com-
pared with survivors. But due to the small number of events, this
information has to be treated with caution.
In contrast to our data, Garcia Bolao et al.,
20 did not ﬁnd any
statistical difference in serum TIMP-l levels between responders
and non-responders to CRT, although TIMP-1 levels tended to
be higher in the non-responder group (563.8+345.7 vs.
437.5+136.5 ng/mL, P ¼ 0.135). The difference in the methods
used in the two studies to determine TIMP-1 concentration
could explain this discrepancy; previous studies
21,22 have shown
that the TIMP-1 concentration differs in serum and in plasma.
It is known that TIMP-1 does more than inhibit MMPs in patients
with chronic heart failure.
23 In chronic inﬂammatory states, TIMP-1
levels increase much more than do MMP levels, promoting col-
lagen formation
24 and myocardial ﬁbrosis.
25,26 Our observations
suggest that patients with higher TIMP-1 levels have more myocar-
dial ﬁbrosis, which could negatively affect the response to CRT.
If our results can be conﬁrmed in larger studies, TIMP-1 could be
usedtoachievebetterselectionofcandidatesforCRTandtoreduce
the percentage of patients who obtain a poor response to CRT.
Figure 1 Correlation between coronary sinus and peripheral vein samples for plasma tissue inhibitor of matrix metalloproteinase-1 concen-
trations (A); and serum matrix metalloproteinase-2 concentrations (B).
Figure 2 Comparison of plasma tissue inhibitor of matrix metalloproteinase-1 levels (A) and serum matrix metalloproteinase-2 levels (B)
according to the aetiology of heart failure.
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levels compared to coronary sinus
samples
WhilemanystudieshavedescribedhighperipheralcirculatingMMP-2
and TIMP -1 levels in patients with heart failure,
8–10,27 to our knowl-
edgethisistheﬁrsttocorrelateperipheralandCSMMP-2andTIMP-1
levels in patients with stable but chronic heart failure.
We found a good correlation between MMP-2 and TIMP-1
samples obtained from the CS and from a peripheral vein.
However, peripheral samples had higher concentrations than the
CS samples, suggesting that MMP-2 and TIMP-1 were not syn-
thesized only in the heart. Although numerous extra-cardiac
factors, including infection, neoplasm, recent surgical intervention,
as well as chronic liver, neuromuscular, and collagen diseases,
could increase MMP and TIMP levels, these factors do not
explain the higher peripheral MMP-2 and TIMP-1 concentration
in our study because we speciﬁcally excluded patients who fulﬁlled
any of these criteria.
Patients with other cardiovascular risk factors, such as diabetes,
dyslipidaemia, and hypertension, also have higher TIMP-1 levels
when compared with healthy subjects.
28,29 The existence of
these factors in most of our patients may explain the difference
between the peripheral and CS TIMP-1 levels.
Based on data obtained in our study, we can conclude that
MMP-2 and TIMP-1 levels in patients with chronic heart failure
are not exclusively markers of cardiac matrix restructuring. It is
possible that MMP-2 and TIMP-1 levels in these patients reﬂected
a greater systemic involvement.
Study limitation
No cardiac biopsies were performed in our patients to assess the
degree of myocardial ﬁbrosis. However, other studies
25,26 have
................................................................................
Table 2 Univariate analysis: predictorsofnon-response
to cardiac resynchronization therapy
Responders
(25)
Non
responders
(17)
P-value
Age 67+96 6 +7 0.78
Creatinine level
(mg/dL)
1.25+0.3 1.76+0.8 0.01*
Atrial ﬁbrillation 6 (24%) 3 (17.6%) 0.47
Ischaemic
cardiomyopathy
10 (40%) 10 (59%) 0.31
Ventricular
arrhythmia
10 (40%) 6 (24%) 0.8
ICD 16 (64%) 10 (59%) 0.57
Beta-blockers 18 (68%) 11 (65%) 0.82
ACEIs–ARBs 20 (80%) 14 (82%) 0.83
Aldosterone 12 (48%) 9 (53%) 0.65
NYHA functional
class IV
2 (8%) 3 (17.6%) 0.38
Basal 6MWDT 248+133 212+117 0.4
QoL test 36+21 48+26 0.45
Post-stimulation
QRS width
142+14 147+24 0.18
LVEDV (mL) 218+61 211+80 0.76
LVESV (mL) 162+74 167+60 0.83
LVEF 27+62 5 +8 0.37
Severe mitral
regurgitation
4 (16%) 1 (6%) 0.32
CS TIMP-1 (ng/mL) 205+51 260+60 0.003*
CS MMP-2 (ng/mL) 239+78 312+70 0.05*
Peripheral TIMP-1
(ng/mL)
216+50 277+59 0.001*
Peripheral MMP-2
(ng/mL)
258+56 325+116 0.02*
ICD, internal cardioverter deﬁbrillator; 6MWDT, 6 min walking distance test;
QoL, quality of life test (Minnesota); LVEDV, left ventricular end-diastolic volume;
LVESV, left ventricular end-systolic volume; LVEF, left ventricular ejection fraction;
CS, coronary sinus; MMP-2, matrix metalloproteinase-2; TIMP-1, tissue inhibitor
matrix metalloproteinase-1; ACEIs, angiotensin converting enzyme inhibitors;
ARBs, angiotensin receptor blockers.
*P , 0.05 responders vs. non-responders.
Figure 3 Receiver-operating characteristic curve of TIMP-1 for
determining lack of response to cardiac resynchronization
therapy.
................................................................................
Table 3 Correlation between MMP-2 and TIMP-1
levels and presence of left ventricular reverse
remodelling (LVESV reduction ≥10%) at 12-month
follow-up
LVESV ≥10%
(23)
LVESV <10%
(19)
P-value
CS TIMP-1 (ng/mL) 192+47 258+55 0.001*
Peripheral TIMP-1
(ng/mL)
208+46 267+60 0.001*
CS MMP-2 (ng/mL) 230+55 307+100 0.08
Peripheral MMP-2
(ng/mL)
267+63 299+100 0.32
CS, coronary sinus; MMP-2, matrix metalloproteinase-2; TIMP-1, tissue inhibitor
matrix metalloproteinase-1; LVESV ≥ 10%, left ventricular end-systolic volume
reduction ≥10%, no death and no transplant; LVESV , 10%, left ventricular
end-systolic volume reduction less than 10% or death or heart transplant.
*P , 0.05.
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ﬁbrosis.
Our study was designed to determine whether basal TIMP-1 and
MMP-2 levels differed between responders and non-responders to
CRT. Due to the small number of patients included in our study,
larger studies will be necessary to deﬁnitively establish a cut-off
TIMP-1 level for optimal sensitivity and speciﬁcity to determine
the probability for lack of response to CRT.
Like most other CRT studies, the follow-up at which response
was assessed in our study was limited to the ﬁrst 12 months
after the implant.
Conclusions
TIMP-1 was an independent predictor of non-response in patients
treated with CRT. TIMP-1 and MMP-2 were higher in patients who
did not respond to CRT. Peripheral MMP-2 and TIMP-1 levels are
higher than levels obtained from the CS in patients with chronic
heart failure.
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